Anti-cldn18.2 antibody and uses thereof
The anti-CLDN18.2 antibody addresses the need for improved gastric cancer treatments by inducing targeted cell killing through ADCC and CDC, enhancing therapeutic efficacy with reduced toxicity.
AU2018447127B2Pending Publication Date: 2026-07-23SHANGHAI GENBASE BIOTECH CO LTD
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- SHANGHAI GENBASE BIOTECH CO LTD
- Filing Date
- 2018-10-22
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
Current treatments for gastric cancer lack effective therapeutic targets, with existing drugs like HER2 and PD-1 antibodies showing limited efficacy, and there is a need for more specific and less toxic antibodies targeting CLDN18.2 for improved cancer immunotherapy.
Method used
Development of an anti-CLDN18.2 antibody or antigen-binding fragments with specific CDR sequences that induce ADCC and CDC, providing high affinity and specificity for CLDN18.2 expression, while minimizing toxicity and side effects.
Benefits of technology
The anti-CLDN18.2 antibody effectively kills tumor cells expressing CLDN18.2 through ADCC and CDC, offering a promising treatment option with enhanced clinical efficacy and reduced side effects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000001_0000 
Figure 00000098_0000 
Figure 00000099_0000
Abstract
Provided are an anti-CLDN18.2 antibody or an antigen binding fragment thereof, a nucleic acid molecule encoding the antibody, and an immunoconjugate comprising same, a bispecific molecule, a chimeric antigen receptor and a pharmaceutical composition. The antibody or antigen binding fragment thereof is used for preventing and / or treating tumors.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
WO2016165762A1
WO2016198835A1